December 3, 2013
Progenitor Cell Therapy LLC (“PCT”), Expands Manufacturing Relationship with ImmunoCellular Therapeutics for Dendritic Cell Vaccines
New Process Development Improvements Intended to Ensure Phase 3 and Commercial Readiness for Client New York, NY, December 3, 2013-- NeoStem, Inc. (Nasdaq:NBS), and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), announced the expansion of PCT’s relationship with ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC), a clinical-stage company that is developing immune-based ...